Identifying genetic factors affecting ADHD treatment response
Official title: Pharmacogenomics of Stimulant Treatment Response in Children and Adolescents With Attention-Deficit/ Hyperactivity Disorder
Run by University of Calgary · NCT06221358 · Data updated 2026-11-12
This study is trying to find out if certain genes affect how well kids and young adults with ADHD respond to a common medication called methylphenidate.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 6 Years to 24 Years |
| Sex | All |
| Enrollment | 400 (estimated) |
| Sponsor | University of Calgary Academic / other |
| Locations | 1 site (Calgary, Alberta) |
| Status | Recruiting |
| Started | April 1, 2024 |
| Main results expected | August 31, 2028 |
| Study ends | December 31, 2028 |
| Registry record updated | October 29, 2026 |
| Trial ID | NCT06221358 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are children and adolescents aged 6 to 24 with a primary diagnosis of ADHD who are starting treatment with methylphenidate.
✕Probably not a fit
Patients with co-occurring severe mental health disorders or those with specific medical histories may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The Pharmacogenomics of Stimulant Treatment Response study aims to uncover genetic profiles that influence how children and adolescents respond to methylphenidate, a common medication for ADHD. By focusing on individuals aged 6 to 24, the study seeks to establish a connection between genetic markers and treatment outcomes, which could lead to more personalized and effective ADHD management. The research will also create a platform for discovering additional genetic and non-genetic factors that impact mental health treatment in young patients.
Why it matters
Potential benefit: If successful, this study could lead to more tailored ADHD treatments, improving efficacy and reducing side effects for patients.
How similar studies have gone: While pharmacogenomic approaches in other areas of psychiatry have shown promise, this specific focus on ADHD treatment response is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Patients will be eligible for participation if all the following are true. * Aged 6 - 24 years. * Located in Canada. * Primary diagnosis of ADHD (all types). * Starting Methylphenidate (excluding immediate release forms) treatment. Exclusion Criteria: Patients will be excluded from participation if any of the following are true. * Co-occurring psychotic, bipolar or eating disorders. * Significant risk of suicide. * An intellectual disability, or diagnosis of autism spectrum disorder (ASD) or tics/Tourette disorders. * Past 12-month high-risk alcohol or substance use defined as monthly or more frequent use. * Psychotherapy or brain stimulation-based therapy initiated within 8 weeks of referral or plans to initiate/change these types of therapies during the study * History of liver or bone marrow (hematopoietic cell) transplant as these events can result in ambiguous genomic results.
Where it's running
-
University of Calgary
Calgary, Alberta, Canada Recruiting
Study contacts
- Principal investigator: Chad Bousman, MPH, PhD — University of Calgary
- Study coordinator: Weng-Sam Siu, MSPT, MSc
- Email: sam.siu@ucalgary.ca
- Phone: 5875739747
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Micronutrient and Chronotherapy for ADHD in children ages 6-12
This 12-week trial tests whether a broad-spectrum vitamin/mineral supplement plus guidance on sleep and meal timing can help reduce ADHD symptoms in children aged 6–12.
-
Home-based brain-controlled game therapy for children with ADHD
This study will test whether home-based brain-controlled game therapy can help reduce core ADHD symptoms in children aged 7 to 11 with mild to moderate ADHD.
-
Probiotics for children with ADHD: gut-brain axis impact
This study tests whether daily probiotics help kids with ADHD by influencing the gut-brain connection, compared with a placebo.
-
Predicting ADHD in middle-school children from foot pressure and posture measurements
Researchers will try to see if foot pressure and posture measurements can help predict ADHD in middle-school-aged children.
-
Virtual reality and simulator training to reduce distracted driving in teens with ADHD
This program will test two training approaches—one using virtual reality and one using a driving simulator—to help licensed teens with ADHD keep their eyes on the road and reduce crash risk.
-
Evaluating EB-1020 for treating adult ADHD
This study is testing if a new medication called EB-1020 can help adults with ADHD manage their symptoms better than a placebo.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.